JP6518656B2 - 標的生体実体を標的にする生化学実体候補をスクリーニングする方法 - Google Patents

標的生体実体を標的にする生化学実体候補をスクリーニングする方法 Download PDF

Info

Publication number
JP6518656B2
JP6518656B2 JP2016519703A JP2016519703A JP6518656B2 JP 6518656 B2 JP6518656 B2 JP 6518656B2 JP 2016519703 A JP2016519703 A JP 2016519703A JP 2016519703 A JP2016519703 A JP 2016519703A JP 6518656 B2 JP6518656 B2 JP 6518656B2
Authority
JP
Japan
Prior art keywords
candidate
shg
biochemical
signature
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016519703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527486A5 (enExample
JP2016527486A (ja
Inventor
ジョシュア サラフスキー，
ジョシュア サラフスキー，
カール ベントン ザ サード ムーア，
カール ベントン ザ サード ムーア，
Original Assignee
バイオデシー， インコーポレイテッド
バイオデシー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオデシー， インコーポレイテッド, バイオデシー， インコーポレイテッド filed Critical バイオデシー， インコーポレイテッド
Publication of JP2016527486A publication Critical patent/JP2016527486A/ja
Publication of JP2016527486A5 publication Critical patent/JP2016527486A5/ja
Application granted granted Critical
Publication of JP6518656B2 publication Critical patent/JP6518656B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2016519703A 2013-06-13 2014-06-13 標的生体実体を標的にする生化学実体候補をスクリーニングする方法 Active JP6518656B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361834782P 2013-06-13 2013-06-13
US61/834,782 2013-06-13
PCT/US2014/042428 WO2014201435A1 (en) 2013-06-13 2014-06-13 Method of screening candidate biochemical entities targeting a target biochemical entity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019081077A Division JP2019135498A (ja) 2013-06-13 2019-04-22 標的生体実体を標的にする生化学実体候補をスクリーニングする方法

Publications (3)

Publication Number Publication Date
JP2016527486A JP2016527486A (ja) 2016-09-08
JP2016527486A5 JP2016527486A5 (enExample) 2017-07-27
JP6518656B2 true JP6518656B2 (ja) 2019-05-22

Family

ID=52022828

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016519703A Active JP6518656B2 (ja) 2013-06-13 2014-06-13 標的生体実体を標的にする生化学実体候補をスクリーニングする方法
JP2019081077A Pending JP2019135498A (ja) 2013-06-13 2019-04-22 標的生体実体を標的にする生化学実体候補をスクリーニングする方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019081077A Pending JP2019135498A (ja) 2013-06-13 2019-04-22 標的生体実体を標的にする生化学実体候補をスクリーニングする方法

Country Status (6)

Country Link
US (1) US20150330990A1 (enExample)
EP (1) EP3008465B1 (enExample)
JP (2) JP6518656B2 (enExample)
CN (1) CN105659087B (enExample)
GB (1) GB2538216A (enExample)
WO (1) WO2014201435A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
CA2831136A1 (en) 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
US9395358B2 (en) 2012-02-05 2016-07-19 Biodesy, Inc. Methods for detecting allosteric modulators of protein
US20130288271A1 (en) 2012-04-25 2013-10-31 Biodesy, Llc Methods for detecting allosteric modulators of protein
WO2013115867A1 (en) 2012-02-05 2013-08-08 Biodesy, Llc Methods for identifying modulators of ras using nonlinear techniques
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
EP3161168B1 (en) 2014-06-30 2021-08-04 Bluelight Therapeutics, Inc. Systems and methods for high throughput analysis of conformation in biological entities
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2016049524A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3237906B8 (en) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
CN107615047A (zh) 2015-04-02 2018-01-19 比奥德赛公司 利用表面选择性非线性光学技术确定蛋白质结构的方法
EA201792214A1 (ru) 2015-04-10 2018-01-31 Араксис Фарма Ллк Соединения замещенного хиназолина
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017053567A1 (en) * 2015-09-22 2017-03-30 Delta Tm Technologies Designing customized protein-specific buffer systems
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤をスクリーニングするための方法
TW201726656A (zh) 2015-11-16 2017-08-01 亞瑞克西斯製藥公司 包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
EP3455628A4 (en) 2016-05-09 2019-12-04 Biodesy, Inc. METHOD AND DEVICES FOR DETECTING INTERACTIONS OF PERIPHERAL MEMBRANE PROTEINS USING NONLINEAR OPTICAL TECHNIQUES
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
CN106650209B (zh) * 2016-09-30 2020-07-07 中车南京浦镇车辆有限公司 一种车辆应用实时信息确定可靠性增长趋势及参数的方法
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
CN106650317B (zh) * 2016-10-09 2019-04-16 南京双运生物技术有限公司 一种通过协同过滤公共数据库发现肿瘤潜在基因标靶的方法
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018195134A1 (en) * 2017-04-18 2018-10-25 X-Chem, Inc. Methods for identifying compounds
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
WO2018218071A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
TW201900633A (zh) 2017-05-25 2019-01-01 美商亞瑞克西斯製藥公司 Kras之共價抑制劑
US10657525B2 (en) 2017-06-27 2020-05-19 Kasisto, Inc. Method and apparatus for determining expense category distance between transactions via transaction signatures
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
US20230236170A1 (en) * 2019-10-15 2023-07-27 Jnana Therapeutics Inc. Reactive affinity probe-interaction discovery platform
CN112630444B (zh) * 2020-12-11 2024-05-24 深圳碳云智肽药物科技有限公司 基于靶点蛋白的多肽筛选方法
CN113963745A (zh) * 2021-12-07 2022-01-21 国际竹藤中心 一种构建植物发育分子调控网络的方法及其应用
CN114317669A (zh) * 2022-01-04 2022-04-12 北京大学 一种基于细胞内蛋白激酶c激活状态筛选药物的方法及高通量筛选装置
WO2024129721A1 (en) * 2022-12-13 2024-06-20 Lafond David Systems and methods to predict biological receptor signal response

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505798A (ja) * 1996-02-01 2000-05-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド コルチコトロピン放出因子の内因性レベルを上昇させる方法
CA2414572A1 (en) * 2000-07-12 2002-01-17 Karo Bio Usa, Inc. Method of identifying conformation-sensitive binding peptides and uses thereof
US20020094528A1 (en) * 2000-11-29 2002-07-18 Salafsky Joshua S. Method and apparatus using a surface-selective nonlinear optical technique for detection of probe-target interations
US20030129649A1 (en) * 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
GB0117326D0 (en) * 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US20030148391A1 (en) * 2002-01-24 2003-08-07 Salafsky Joshua S. Method using a nonlinear optical technique for detection of interactions involving a conformational change
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
EP1637885A1 (en) 2004-09-16 2006-03-22 Vivalis Method of screening by using conformation sensitive peptides
US7968091B2 (en) * 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
US20070238184A1 (en) * 2005-06-16 2007-10-11 The Regents Of The University Of California Amyloid beta protein channel structure and uses thereof in identifying potential drug molecules for neurodegenerative diseases
US20090010894A1 (en) * 2005-12-23 2009-01-08 The Parkinson's Institute Methods and systems for identifying compounds that modulate alpha-synuclein aggregation
AU2007277186B2 (en) * 2006-07-28 2014-01-30 Presympto, Inc. Peptide probes for diagnostics and therapeutics
EP2326728A1 (en) * 2008-07-24 2011-06-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Fluorescently or spin-labeled kinases for rapid screening and identification of novel kinase inhibitor scaffolds
US9182406B2 (en) * 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
WO2010031185A1 (en) * 2008-09-19 2010-03-25 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
CA2831136A1 (en) * 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
CN106290917B (zh) * 2012-04-25 2020-06-05 比奥德赛公司 用于检测蛋白质的变构调节剂的方法

Also Published As

Publication number Publication date
EP3008465A4 (en) 2017-02-15
JP2016527486A (ja) 2016-09-08
CN105659087B (zh) 2019-09-17
GB2538216A (en) 2016-11-16
WO2014201435A8 (en) 2016-04-28
CN105659087A (zh) 2016-06-08
WO2014201435A1 (en) 2014-12-18
EP3008465A1 (en) 2016-04-20
JP2019135498A (ja) 2019-08-15
EP3008465B1 (en) 2019-08-07
US20150330990A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
JP6518656B2 (ja) 標的生体実体を標的にする生化学実体候補をスクリーニングする方法
Bernetti et al. Protein–ligand (un) binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling
JP6302460B2 (ja) タンパク質のアロステリックモジュレーターを検出するための方法
US9383361B2 (en) Methods for detecting allosteric modulators of protein
Moree et al. Protein conformational changes are detected and resolved site specifically by second-harmonic generation
Song et al. Recent progress in the development of transglutaminase 2 (TGase2) inhibitors: Miniperspective
Somsen et al. Reversible dual-covalent molecular locking of the 14-3-3/ERRγ protein–protein interaction as a molecular glue drug discovery approach
Hill et al. Direct proximity tagging of small molecule protein targets using an engineered NEDD8 ligase
US9428789B2 (en) Classification of kinase inhibitors using nonlinear optical techniques
US20110212475A1 (en) Fluorescently Or Spin-Labeled Kinases For Rapid Screening And Identification Of Novel Kinase Inhibitor Scaffolds
US20160356767A1 (en) Methods for detecting allosteric modulators of protein
US20110246078A1 (en) Mitochondria katp ion channel as a drug target for preventing liver diseases and methods to screen mitochondria katp modulators
Nicolini et al. Determination of proteinprotein interaction for cancer control via mass spectrometry an d nanoconductimetry of NAPPA SNAP arrays: an overview
Huber et al. Elucidation of direct competition and allosteric modulation of small‐molecular‐weight protein ligands using surface plasmon resonance methods
Roberto et al. NMR Screening Methods in Fragment-Based Drug Discovery
Shraga First of Their Kind Covalent Chemical Probes Targeting Kinases (MKK7/BTK) For Inhibition or Degradation
AU2012234209A1 (en) Kinases labeled in the C helix for the screening of inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170612

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190422

R150 Certificate of patent or registration of utility model

Ref document number: 6518656

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250